Compare APVO & EEIQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APVO | EEIQ |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.8M |
| IPO Year | 2023 | 2019 |
| Metric | APVO | EEIQ |
|---|---|---|
| Price | $2.45 | $2.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 45.0K | 8.3K |
| Earning Date | 05-11-2026 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,114,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.15 |
| 52 Week High | $10.70 | $12.70 |
| Indicator | APVO | EEIQ |
|---|---|---|
| Relative Strength Index (RSI) | 29.47 | 56.11 |
| Support Level | $2.30 | $2.45 |
| Resistance Level | $4.84 | $2.91 |
| Average True Range (ATR) | 0.22 | 0.20 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 13.50 | 73.16 |
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
EpicQuest Education Group International Ltd provides comprehensive education solutions for domestic and international students interested in university and college degree programs in the U.S, Canada, and the UK. In addition, the company has a recruiting relationship with the regional campuses of Miami University of Ohio, where it maintains residential facilities, a full-service cafeteria, recreational facilities, shuttle buses, and an office for the regional campuses that provides study abroad and post-study services for its students; these facilities are not owned, maintained, operated or are part of Miami University. The Company's revenue is derived from foreign education programs, university education programs and student accommodation services.